Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Prospective, Intra-patient Randomised Controlled, Multicentre Study to Evaluate the Safety and Efficacy of an Autologous Bio-engineered Dermo-epidermal Skin Substitute (EHSG-KF) for the Treatment of Full-Thickness Defects in Adults and Children in Comparison to Autologous Split-thickness Skin Grafts (STSG)

NCT03394612 is registered in ClinicalTrials.gov with CUTISS AG as lead sponsor.

NCT NCT03394612
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03394612 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Prospective, Intra-patient Randomised Controlled, Multicentre Study to Evaluate the Safety and Efficacy of an Autologous Bio-engineered Dermo-epidermal Skin Substitute (EHSG-KF) for the Treatment of Full-Thickness Defects in Adults and Children in Comparison to Autologous Split-thickness Skin Grafts (STSG)
Lead sponsor
CUTISS AG
Phase
Phase 2
Overall status
Completed
Start date
February 14, 2018
Completion date
August 21, 2026
Enrollment
21 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

skin wound